Differential translation of mRNA isoforms underlies oncogenic activation of cell cycle kinase Aurora A.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37384380.
- Also identified by DOI 10.7554/eLife.87253 and PMC identifier 10328522.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Aurora Kinase A (AURKA) is an oncogenic kinase with major roles in mitosis, but also exerts cell cycle- and kinase-independent functions linked to cancer. Therefore, control of its expression, as well as its activity, is crucial. A short and a long 3'UTR isoform exist for AURKA mRNA, resulting from alternative polyadenylation (APA). We initially observed that in triple-negative breast cancer, where AURKA is typically overexpressed, the short isoform is predominant and this correlates with faster relapse times of patients. The short isoform is characterized by higher translational efficiency since translation and decay rate of the long isoform are targeted by <i>hsa-let-7a</i> tumor-suppressor miRNA. Additionally, <i>hsa-let-7a</i> regulates the cell cycle periodicity of translation of the long isoform, whereas the short isoform is translated highly and constantly throughout interphase. Finally, disrupted production of the long isoform led to an increase in proliferation and migration rates of cells. In summary, we uncovered a new mechanism dependent on the cooperation between APA and miRNA targeting likely to be a route of oncogenic activation of human AURKA.
Medical subject headings
- Aurora Kinase A
- MicroRNAs